See the DrugPatentWatch profile for ozempic

Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, used primarily for the treatment of type 2 diabetes. It has been found to reduce the risk of cardiovascular events in patients with type 2 diabetes and established cardiovascular disease [1].

According to a study published in the New England Journal of Medicine, Ozempic reduced the risk of major adverse cardiovascular events by 26% in patients with type 2 diabetes and established cardiovascular disease, compared to placebo [2]. These events included cardiovascular death, non-fatal heart attack, or non-fatal stroke.

Compared to other treatments, Ozempic has shown superior cardiovascular risk reduction. For instance, a network meta-analysis published in the Journal of the American College of Cardiology found that Ozempic had the highest probability of being the most effective GLP-1 receptor agonist in reducing major adverse cardiovascular events [3].

However, it's important to note that while Ozempic has shown promising results in reducing cardiovascular risk, it should not be used as a substitute for other proven preventative measures such as maintaining a healthy diet, regular exercise, and controlling blood pressure and cholesterol levels [4].

In summary, Ozempic has been shown to reduce the risk of cardiovascular events in patients with type 2 diabetes and established cardiovascular disease, and it has shown superior cardiovascular risk reduction compared to other treatments.

Sources:
[1] DrugPatentWatch.com, "Ozempic (semaglutide) - Cardiovascular Risk Reduction", <https://www.drugpatentwatch.com/drugs/ozempic>.
[2] Marso, S.P., et al., "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes", New England Journal of Medicine, 2016, <https://www.nejm.org/doi/full/10.1056/NEJMoa1607919>.
[3] Zheng, Y., et al., "Comparative Effectiveness and Safety of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review, Network Meta-Analysis, and Meta-Regression", Journal of the American College of Cardiology, 2018, <https://www.jacc.org/doi/full/10.1016/j.jacc.2018.03.053>.
[4] American Heart Association, "How to Prevent Heart Disease at Any Age", <https://www.heart.org/en/healthy-living/healthy-lifestyle/how-to-help-prevent-heart-disease-at-any-age>.